Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1515-1524 , December 2007

CD3+ Cell Dose and Disease Status Are Important Factors Determining Clinical Outcomes in Patients Undergoing Unmanipulated Haploidentical Blood and Marrow Transplantation after Conditioning Including Antithymocyte Globulin

  • Lujia Dong

      Affiliations

    • Peking University, People's Hospital
    • Dao-Pei Hospital, Beijing, China
    • Corresponding Author InformationCorrespondence and reprint requests: Lujia Dong, MD, Peking University, People's Hospital, No.11 Xizhimen South Street, Beijing 100044, China. Tel: 8610 68792784; Fax: 8610 68333439.
    • ,
  • Tong Wu

      Affiliations

    • Peking University, People's Hospital
    • Dao-Pei Hospital, Beijing, China
    • ,
  • Mei-Jie Zhang

      Affiliations

    • Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA
    • ,
  • Zhi-Yong Gao

      Affiliations

    • Peking University, People's Hospital
    • Dao-Pei Hospital, Beijing, China
    • ,
  • Dao-Pei Lu

      Affiliations

    • Peking University, People's Hospital
    • Dao-Pei Hospital, Beijing, China

Received 6 June 2007 ,Accepted 9 September 2007.

References 

  1. Barnes DWH, Corp MJ, Loutit JF, et al. Treatment of murine leukemia with x-rays and homologous bone marrow: preliminary communication. BMJ. 1956;2:626–627
  2. Appelbaum FR. Hematopoietic cell transplantation as a form of immunotherapy. Int J Hematol. 2002;75:222–227
  3. Bortin MM, Gale RP, Kay HEM, et al. Bone marrow transplantation for acute myelogenous leukemia. JAMA. 1983;249:1166–1175
  4. Dominietto A, Lamparelli T, Raiola AM, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:3930–3934
  5. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood. 2001;97:383–387
  6. Mohty M, Bagattini S, Chabannon C, et al. CD8+ T-cell dose affects development of acute graft-versus-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol. 2004;32:1097–1102
  7. Schuening F, Miller AD, Torok-Storb B, et al. Study on contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after transplantation. Hum Gene Ther. 1994;5:1523–1534
  8. Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000;18:1360–1377
  9. Aversa F, Martelli MM, Reisner Y. Use of stem cells from mismatched related donors. Curr Opin Hematol. 1997;4:419–422
  10. Cao TM, Wong RM, Sheehan K, et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol. 2005;33:279–285
  11. Handgretinger R, Schumm M, Lang P, et al. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci. 1999;872:351–362
  12. Tabilio A, Falzetti F, Zei T, et al. Graft engineering for allogeneic haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:274–280
  13. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by un-manipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes to HLA-identical sibling transplantation. Blood. 2006;107(8):3065–3073
  14. Drach J, Zhao S, Drach D, et al. Expression of MDR by normal bone marrow cells and its implication for leukemia hematopoiesis. Leukemia Lymphoma. 1995;16:419–424
  15. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. New Engl J Med. 1975;292:832–843895-902
  16. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood. 1988;71:293–298
  17. Glucksberg H, Fefer RS, Buckner CD, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304
  18. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–259
  19. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  20. Ichinohe T, Uchiyama T, Shimazaki C, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood. 2004;104:3821–3828
  21. Van Rood JJ, Claas F. Noninherited maternal HLA antigens: a proposal to elucidate their role in the immune response. Hum Immunol. 2000;61:1390–1394
  22. Marks DI, Aversa F, Lazarus HM. Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant. 2006;38:467–475
  23. Aversa F, Terenzi A, Felicini R, et al. Haploidentical stem cell transplantation for acute leukemia. Int J Hematol. 2002;76(Suppl 1):165–168
  24. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433–440
  25. Marks DI, Khattry N, Cummins M, et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol. 2006;134:196–201
  26. Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006;108:1797–1808
  27. Naujokat C, Berges C, Fuchs D, et al. Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation. 2007;83:485–497
  28. Seidel MG, Fritsch G, Matthes-Martin S, et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2005;27:532–536
  29. Waller EK, Langston AA, Lonial S, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2003;9:460–471
  30. Remberger M, Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica. 2005;90:869B
  31. Serody JS, Sparks SD, Lin Y, et al. Comparison of granulocyte colony-stimulating factor (G-CSF)–mobilized peripheral blood progenitor cells and G-CSF–stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant. 2000;6:434–440
  32. Ji SQ, Chen HR, Wang HX, et al. G-CSF–primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant. 2002;30:861–866
  33. Huang XJ, Chang JC, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF–mobilized peripheral blood grafts and G-CSF–primed bone marrow grafts in different proportions. Transplant Immunol. 2007;17:193–197
  34. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21:1733–1738
  35. Le Blanc K. Mesenchymal stromal cells: tissue repair and immune modulation. Cytotherapy. 2006;8:559–561
  36. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390–1397
  37. Lazarus HM, Koc ON, Devine SM, et al. Co-transplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology Blood Marrow Transplant. 2005;11:389–398
  38. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–1822
  39. Chung NG, Jeong DC, Park SJ, et al. Co-transplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol. 2004;80:370–376
  40. Gieseke F, Schütt B, Viebahn S, et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNγR1-signaling and IDO expression. Blood. 2007;110(6):2197–2200
  41. Isola LM, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donor stimulated with G-CSF. Bone Marrow Transplant. 1997;20:1033–1037
  42. Couban S, Messner HA, Andreou P, et al. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients. Biol Blood Marrow Transplant. 2000;6:422–427
  43. Saliba RM, Lima MD, Giralt S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109:2751–2758

PII: S1083-8791(07)00455-7

doi: 10.1016/j.bbmt.2007.09.007

Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1515-1524 , December 2007

Article Tools

* Image Usage & Resolution